Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05652335 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Name: A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis — clinical trial record (NCT05652335)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorJanssen Research & Development, LLC

Started2022-11-22

View on ClinicalTrials.gov ↗

The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s) selected and in disease subgroups in Part 2 (dose expansion).

Amendment history 1 change detected by DataLookout

2026-08-29

Completion pushed: 2028-08-28 → 2030-11-15

Trial Details

NCT Number	NCT05652335
Lead Sponsor	Janssen Research & Development, LLC
Conditions	Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
Enrollment	180 participants
Start Date	2022-11-22
Primary Completion	2027-04-19 (estimated)
Study Completion	2030-11-15 (estimated)
Updated on ClinicalTrials.gov	2026-08-28